Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
HIV infection Clinical criteria: Treatment Phase: Initial Patient must be antiretroviral treatment naive, AND The treatment must be in combination with other antiretroviral agents.
Chronic hepatitis B infection Clinical criteria: Patient must not have cirrhosis, AND Patient must have elevated HBV DNA levels greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, in conjunction with documented hepatitis B infection; OR Patient must have elevated HBV DNA levels greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative, in conjunction with documented hepatitis B infection, AND Patient must have evidence of chronic liver injury determined by confirmed elevated serum ALT or liver biopsy.
“Lamivudine-TP acts as a substrate for the HBV viral polymerase. It is considered that the formation of further viral DNA is blocked by incorporation of lamivudine-TP into the chain and subsequent chain termination.”
“The observed half-life of elimination is 5 to 7 hours.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.